EG20747A - Method for preparing galanthamine derivatives as acetylcholinesterase inhibitors - Google Patents

Method for preparing galanthamine derivatives as acetylcholinesterase inhibitors

Info

Publication number
EG20747A
EG20747A EG63794A EG63794A EG20747A EG 20747 A EG20747 A EG 20747A EG 63794 A EG63794 A EG 63794A EG 63794 A EG63794 A EG 63794A EG 20747 A EG20747 A EG 20747A
Authority
EG
Egypt
Prior art keywords
acetylcholinesterase inhibitors
galanthamine derivatives
alkylaminocarbonyloxy
preparing
preparing galanthamine
Prior art date
Application number
EG63794A
Other languages
English (en)
Inventor
Raymond W Kosley Jr
Larry Davis
Veronica Taberna
Original Assignee
Hoechst Marion Roussel Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoechst Marion Roussel Inc filed Critical Hoechst Marion Roussel Inc
Application granted granted Critical
Publication of EG20747A publication Critical patent/EG20747A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Psychiatry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
EG63794A 1993-10-15 1994-10-12 Method for preparing galanthamine derivatives as acetylcholinesterase inhibitors EG20747A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/137,443 US6323196B1 (en) 1993-10-15 1993-10-15 Galanthamine derivatives as acetylcholinesterase inhibitors

Publications (1)

Publication Number Publication Date
EG20747A true EG20747A (en) 2000-01-31

Family

ID=22477457

Family Applications (1)

Application Number Title Priority Date Filing Date
EG63794A EG20747A (en) 1993-10-15 1994-10-12 Method for preparing galanthamine derivatives as acetylcholinesterase inhibitors

Country Status (24)

Country Link
US (1) US6323196B1 (de)
EP (2) EP1020469A3 (de)
JP (1) JP2718637B2 (de)
KR (1) KR100189043B1 (de)
CN (1) CN1039011C (de)
AT (1) ATE201687T1 (de)
AU (1) AU679560B2 (de)
CA (1) CA2118171C (de)
CZ (1) CZ283561B6 (de)
DE (1) DE69427332T2 (de)
DK (1) DK0648771T3 (de)
EG (1) EG20747A (de)
ES (1) ES2158876T3 (de)
FI (1) FI108724B (de)
GR (1) GR3036068T3 (de)
IL (1) IL111273A (de)
NO (1) NO307463B1 (de)
NZ (1) NZ264681A (de)
PL (1) PL177754B1 (de)
PT (1) PT648771E (de)
RO (1) RO114132B1 (de)
RU (1) RU2113438C1 (de)
TW (1) TW375615B (de)
ZA (1) ZA948060B (de)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT403803B (de) 1996-04-19 1998-05-25 Sanochemia Ltd Neue benzazepinderivate, diese enthaltende arzneimittel und verwendung derselben zum herstellen von arzneimitteln
WO2000030446A1 (en) 1998-11-23 2000-06-02 Bonnie Davis Dosage formulations for acetylcholinesterase inhibitors
EP1140105B1 (de) 1998-12-24 2003-10-22 Janssen Pharmaceutica N.V. Galantamin-zusammensetzung mit gesteuerter freisetzung
AU780012B2 (en) * 1999-12-10 2005-02-24 Bonnie Davis Analogs of galanthamine and lycoramine as modulators of nicotinic receptors
CN1380883A (zh) 2000-03-31 2002-11-20 萨诺化学药物股份公司 雪花胺的新衍生物和类似物
US20030162770A1 (en) * 2002-02-22 2003-08-28 Davis Bonnie M. Use of modulators of nicotinic receptors for treatment of cognitive dysfunction
US20040142970A1 (en) * 2002-11-01 2004-07-22 Kathryn Chung Treatment of hyperkinetic movement disorder with donepezil
US20050048543A1 (en) * 2003-07-11 2005-03-03 Jeroen Aerssens CHRNA2 genetic markers associated with galantamine response
WO2005042762A2 (en) * 2003-10-28 2005-05-12 Genaissance Pharmaceuticals, Inc. Lrpap1 genetic markers associated with galantamine response
US20050143350A1 (en) * 2003-11-19 2005-06-30 Seed John C. Combination drug therapy to treat obesity
US7250258B2 (en) * 2003-12-15 2007-07-31 Pgxhealth Llc CDK5 genetic markers associated with galantamine response
CA2552114A1 (en) * 2003-12-31 2005-07-21 Actavis Group Hf Solid dosage formulations of galantamine
US20050191349A1 (en) * 2003-12-31 2005-09-01 Garth Boehm Galantamine formulations
EP1779867A4 (de) * 2004-07-01 2009-12-02 Eisai R&D Man Co Ltd Mittel zur förderung der nervenreveneration
DK1895994T3 (da) * 2005-05-13 2010-12-20 Alza Corp Multilagsmedikamentleveringssystem med barriere mod reservoirmaterialeflow
US20080188510A1 (en) * 2005-05-23 2008-08-07 Eisai R & D Management Co., Ltd. Novel methods using zonisamide
EP1777222A1 (de) * 2005-09-22 2007-04-25 Galantos Pharma GmbH Cholinesterase Inhibitoren mit erhöter Blut Hirn Schranke Permeabilität zur Behandlung von kognitiven Störungen
US20090253654A1 (en) 2005-09-22 2009-10-08 Galantos Pharma Gmbh Cholinergic enhancers with improved blood-brain barrier permeability for the treatment of diseases accompanied by cognitive impairment
WO2007035941A2 (en) * 2005-09-23 2007-03-29 Alza Corporation Transdermal galantamine delivery system
KR100786371B1 (ko) * 2006-12-07 2007-12-17 한국화학연구원 갈란타민의 제조방법
EP2137192B8 (de) 2008-04-14 2014-06-11 Neurodyn Life Sciences Inc. Galantaminderivate als Prodrug-Verbindungen zur Behandlung humaner Hirnerkrankungen
US20120184532A1 (en) * 2009-07-23 2012-07-19 Shire Llc Galantamine amino acid and peptide prodrugs and uses thereof
US12551491B1 (en) * 2025-07-23 2026-02-17 Alpha Cognition Inc. Dosage regimens for benzgalantamine

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL122665B1 (en) 1978-11-21 1982-08-31 Edinen Zentar Chim Process for preparing novel dienones of narvedine type and their derivatives
US4663318A (en) 1986-01-15 1987-05-05 Bonnie Davis Method of treating Alzheimer's disease
US6150354A (en) * 1987-01-15 2000-11-21 Bonnie Davis Compounds for the treatment of Alzheimer's disease
DE3856594D1 (de) * 1987-05-04 2008-11-27 Bonnie Davis Mittel zur behandlung der alzheimer-krankheit
NL8800350A (nl) 1988-02-12 1989-09-01 Stichting Biomedical Research Synthetische galanthamine-derivaten, werkwijze voor het bereiden daarvan, en farmaceutische samenstellingen.
DE69229781T2 (de) 1991-05-14 2000-01-05 Ernir Snorrason Behandlung des ermüdungssyndroms mit cholinesteraseinhibitoren
US5336675A (en) * 1991-05-14 1994-08-09 Ernir Snorrason Method of treating mania in humans
US5153193A (en) 1991-10-01 1992-10-06 Hoechst-Roussel Pharmaceuticals Incorporated Carbamate derivatives of 4-amino-3-isoxazolidinones, 3-amino-1-hydroxypyrrolidin-2-ones and 1-amino-1-cyclopropanecarboxylic acid analogs
US5231093A (en) * 1991-10-01 1993-07-27 Hoechst-Roussel Pharmaceuticals Incorporated Carbamate derivatives of 4-amino-3-isoxazolidinones, 3-amino-1-hydroxypyrrolidin-2-ones and 1-amino-1-cyclopropanecarboxylic acid analogs

Also Published As

Publication number Publication date
ATE201687T1 (de) 2001-06-15
JP2718637B2 (ja) 1998-02-25
PT648771E (pt) 2001-09-28
EP1020469A2 (de) 2000-07-19
NO307463B1 (no) 2000-04-10
IL111273A0 (en) 1994-12-29
EP0648771B1 (de) 2001-05-30
KR100189043B1 (ko) 1999-06-01
FI944822L (fi) 1995-04-16
KR950011444A (ko) 1995-05-15
US6323196B1 (en) 2001-11-27
PL305455A1 (en) 1995-04-18
EP1020469A3 (de) 2000-07-26
RO114132B1 (ro) 1999-01-29
IL111273A (en) 1998-04-05
CA2118171A1 (en) 1995-04-16
JPH07188238A (ja) 1995-07-25
TW375615B (en) 1999-12-01
ZA948060B (en) 1995-06-09
GR3036068T3 (en) 2001-09-28
PL177754B1 (pl) 2000-01-31
FI944822A0 (fi) 1994-10-13
EP0648771A1 (de) 1995-04-19
DE69427332T2 (de) 2001-10-11
NO943894L (no) 1995-04-18
FI108724B (fi) 2002-03-15
CN1108658A (zh) 1995-09-20
AU679560B2 (en) 1997-07-03
RU2113438C1 (ru) 1998-06-20
ES2158876T3 (es) 2001-09-16
CA2118171C (en) 1999-12-28
NZ264681A (en) 1997-12-19
RU94036761A (ru) 1996-09-10
CZ254794A3 (en) 1995-05-17
CZ283561B6 (cs) 1998-05-13
NO943894D0 (no) 1994-10-14
AU7581294A (en) 1995-05-04
DK0648771T3 (da) 2001-08-27
CN1039011C (zh) 1998-07-08
DE69427332D1 (de) 2001-07-05

Similar Documents

Publication Publication Date Title
GR3036068T3 (en) Galanthamine derivatives, a process for their preparation and their use as medicaments.
CA2322944A1 (en) Functionalized alkyl and alkenyl side chain derivatives of glycinamides as farnesyl transferase inhibitors
TW254943B (de)
TW264477B (de)
EG20472A (en) Process for preparing of golanthamine derivatives a acitylcholinesterase inhibitors
AU3744397A (en) Total synthesis of antitumor acylfulvenes
AU2722095A (en) Novel pyrrolocarbazoles
AU586867B2 (en) Biocidal mixture
AU1765288A (en) Cycloalkylamides of (8beta)-1-isopropyl-6-(substituted) ergolines
AU647218B2 (en) Process for the preparation of insecticidal, acaricidal and molluscicidal 2-halopyrrole-3-carbonitrile compounds
EP0555479A4 (de)
EP1028118A4 (de) Verfahren zur herstellung von 3-cephem-verbindungen
ES2144327T3 (es) Procedimiento para preparar un compuesto de 2-cianobifenilo.
NZ233196A (en) Process for preparing glutaric acid derivatives and 2-alkoxycarbonylalkyl cyclohexanone derivatives
EP0590681A3 (en) A process for the preparation of aminothiadiazolylacetyl halide derivatives
EP0573659A4 (en) Pyrazolothiazolopyrimidine derivative
TW239123B (de)